News | Renal Denervation | December 09, 2020

FDA Grants Breakthrough Device Designation for the TIVUS Renal Artery Denervation System

SoniVie acquires new intellectual property from Cardiosonic and begins moving TIVUS into new therapeutic areas beyond pulmonary hypertension

SoniVie, an Israeli company developing the Therapeutic Intra-Vascular Ultrasound (TIVUS) System to treat a variety of hypertensive disorders, announced that it has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The  TIVUS System for renal artery denervation treats resistant hypertension, which is defined as blood pressure that remains above 140/90 mmHg despite use of three antihypertensive medications of different classes at the best tolerated doses.

SoniVie, an Israeli company developing the Therapeutic Intra-Vascular Ultrasound (TIVUS) System to treat a variety of hypertensive disorders, announced that it has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).

December 9, 2020 — SoniVie, an Israeli company developing the Therapeutic Intra-Vascular Ultrasound (TIVUS) System to treat a variety of hypertensive disorders, announced that it has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The  TIVUS System for renal artery denervation treats resistant hypertension, which is defined as blood pressure that remains above 140/90 mmHg despite use of three antihypertensive medications of different classes at the best tolerated doses, one of which must be a diuretic. 

Millions of people world-wide suffer from resistant hypertension which substantially increases the risk of heart attack, stroke and kidney failure.

Breakthrough Device Designation is a special regulatory status granted to medical devices that provide a more effective treatment for life-threatening or irreversibly debilitating diseases. The goal of the Breakthrough Devices Program is to provide patients and health care providers with timely access to these medical devices by speeding up their development, assessment, and review, while preserving the statutory standards for FDA premarket approval, 510(k) clearance and de novo marketing authorization. The company previously received Breakthrough Device Designation for the TIVUS System in the treatment of pulmonary arterial hypertension (PAH) in September 2019.

“We are excited about moving the TIVUS System into therapeutic areas beyond PAH and believe that the technology has broad utility in a variety of serious health conditions,” said Chuck Carignan, M.D., chief executive officer at SoniVie. “A growing body of clinical evidence suggests that our ultrasound-based denervation technology may provide clinical benefit in the treatment of diseases that lack optimal medical management, including resistant hypertension. We believe that the TIVUS System can work synergistically with existing treatments to potentially improve clinical outcomes.”

The company also announced that it has acquired the remaining intellectual property and other assets related to the use of the TIVUS System from Cardiosonic. SoniVie had previously licensed technology related to the use of TIVUS specifically in the treatment of PAH.

With this acquisition, SoniVie’s TIVUS procedure becomes the only platform denervation technology with active development programs in multiple therapeutic areas: pulmonary artery denervation (PADN) for pulmonary hypertension and renal artery denervation (RDN) for resistant hypertension along with other potential applications.

Dr. Carignan added, “With Breakthrough Device Designation in two indications and control of the intellectual property and other assets related to the use of the TIVUS System in multiple indications, we have a strong competitive advantage as we work to advance targeted denervation as a therapeutic approach that can provide best-in-class outcomes to patients.”

Renal denervation with the TIVUS System is a minimally invasive procedure that uses high-frequency non-focused ultrasound to ablate nerves in the renal artery. This causes a reduction in the nerve activity, which decreases blood pressure. This procedure is designed for patients who suffer from resistant hypertension. Cardiosonic previously conducted two clinical trials of RDN in patients with resistant hypertension using an earlier version of the TIVUS System, and these trials showed excellent feasibility in lowering blood pressure out to six months. Cardiosonic also received a CE Mark for the earlier version of the system.

“With our very encouraging clinical data in PAH, and the excellent published data from the TIVUS II study in renal artery denervation conducted by Cardiosonic, we may be able to offer a platform solution that can change the lives of millions of people worldwide, while reducing costs to healthcare systems,” said Dr. Irit Yaniv, chair of SoniVie and founding partner and CEO of Almeda Ventures.

Building on the promising RDN clinical trials that Cardiosonic previously conducted, SoniVie expects to initiate new clinical trials of its current TIVUS System in patients with resistant hypertension in late 2021. In October 2020, the company announced that it had received IDE approval for its pivotal trial of the TIVUS System in patients with PAH (NCT04570228), and it currently anticipates initiating enrollment in the study in early 2021.

For more information: sonivie.com

 

Related Renal Denervation Content:

PCR Says Renal Denervation Offers Hope for Noncompliant Hypertension Patients

The Development of Renal Denervation Therapy

VIDEO: New Approaches to Denervation Therapy — Interview with Robert Schwartz, M.D.

Cardiosonic Received CE Mark for TIVUS Ablative Catheter Device

Cardiosonic Begins Enrollment in the TIVUS I Renal Denervation Trial

Simplicity Renal Denervation Lowered Blood Pressure Out to 3 Years
 

Related Content

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

News | Cath Lab | July 22, 2021
July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of
ast End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company's SafeCross Transseptal Radiofrequency (RF) Puncture and Steerable Balloon Introducer System. The 3-in-1 system, which includes a steerable introducer sheath with an ultra-visible positioning balloon and radiofrequency (RF) puncture dilator, aims to provide a predictable and safe solution for electrophysiology (EP) and structural heart interventions requiring left atrial access.
News | Cath Lab | July 14, 2021
July 13, 2021 — East End Medical announced it received U.S.
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A cardiac cath lab complex PCI case at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab | April 28, 2021